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Since the approval and introduction of imatinib as the first molecular-targeted drug for the treatment of
chronic myelogenous leukemia in 2001, more than 50 cancer targeted drugs have been approved in Japan. The
molecular targeted drugs have shown prominent efficacy in several cancers caused by the corresponding target
molecules. Over recent years, development of biomarkers, companion diagnostics, and next generation sequenc-
ing analysis for prediction of clinical outcome facilitated the selection of appropriate drug for patients. The mo-
lecular targeted drugs are classified into two groups, monoclonal antibodies and small molecules, which have vari-
ous mechanisms of action, including inhibition of tyrosine kinases, tumor angiogenesis, and immune checkpoint.
Various mechanisms of action of drugs may also exhibit unique adverse events that have not been previously ob-
served. Continuous changes in cancer genomes lead to tumor heterogeneity, which in turn may fuel drug resis-
tance. To overcome these issues, identification of new therapeutic targets and a large number of clinical trials
with novel designs are in progress for realization of cancer precision medicine. Here, we summarize recent find-
ings of molecular targeted drugs.
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Fig.　1　Development of molecular-targeted drugs in Japan. Red line shows the total num-
ber of approved drugs. Each circle indicates the time of drug approval. The figure was 








































































Fig.　2　The mechanism of action of molecular targeted drugs against cancer. Molecular 
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Generic Name Trade Name
Epidermal growth factor 
receptor (EGFR)
Gefitinib Iressa KI Non-small cell lung cancer (EGFR mutation-positive)
Erlotinib Tarceva KI Non-small cell lung cancer (EGFR/exon19del, L858R), pancreatic cancer
Cetuximab Erbitux Ab, KI Colorectal cancer, head and neck cancer
Panitumumab Vectibix Ab, KI Colorectal cancer
Afatinib Gilotrif KI Non-small cell lung cancer (EGFR /exon19del, L858R)
Osimertinib Tagrisso KI Non-small cell lung cancer (EGFR/ T790M)
Human epidermal growth fac-
tor receptor (Her2)
Trastuzumab Herceptin Ab, KI Breast cancer, gastric cancer
Lapatinib Tykerb KI Breast cancer





Vascular endothelial growth 
factor (VEGF)
Bevacizumab Avastin Ab
Colorectal cancer, non-small cell lung cancer, breast cancer, glioblas-
toma, renal cell carcinoma, ovarian cancer, malignant glioma, cervi-
cal cancer
Ziv-aflibercept Zaltrap Ab-Fc Colorectal cancer
Vascular endothelial growth 
factor receptor 2 (VEGFR2) Ramucirumab Cyramza
Ab, 
KI
Gastric or gastroesophageal junction adenocarcinoma, non-small cell 
lung cancer, colorectal cancer
Multi-kinase (inhibition of 
vascular endothelial growth 
factor receptor: VEGFR, 
platelet-derived growth 
factor receptor: PDGFR, 
c-KIT, Fms-like tyrosine 
kinase 3: Flt-3, RET tyrosine 
kinase: RET, RAF, fibro-
blast growth factor recep-
tor: FGFR)
Sorafenib Nexavar KI Renal cell carcinoma, hepatocellular carcinoma, thyroid cancer
Sunitinib Sutent KI Gastrointestinal stromal tumor (GIST), renal cell carcinoma, neuro-endocrine tumors (NET)
Pazopanib Votrient KI Renal cell carcinoma, advanced soft-tissue sarcoma
Vandetanib Caprelsa KI Medullary thyroid carcinoma
Axitinib Inlyta KI Renal cell carcinoma
Regorafenib Stivarga KI Colorectal cancer, GIST, hepatocellular carcinoma
Nintedanib Vargatef KI Non-small cell lung cancer
Lenvatinib Lenvima KI Thyroid cancer, renal cell carcinoma
BCR-ABL
Imatinib Gleevec KI Chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph＋ ALL), GIST
Dasatinib Sprycel KI CML, Ph＋ ALL
Nilotinib Tasigna KI CML
Bosutinib Bosulif KI CML
Ponatinib Iclusig KI CML, Ph＋ ALL (T315I)
Anaplastic lymphoma 
kinase (ALK)
Crizotinib Xalkori KI Non-small cell lung cancer (ALK/ROS1)
Alectinib Alecensa KI Non-small cell lung cancer (ALK fusion gene)
Ceritinib Zykadia KI Non-small cell lung cancer (ALK fusion gene)
Mammalian target of 
rapamycin (mTOR)
Temsirolimus Torisel KI Renal cell carcinoma
Everolimus Afinitor KI Renal cell carcinoma, subependymal giant cell astrocytoma (SEGA), NET, breast cancer, renal angiomyolipoma
Cytotoxic T-lymphocyte 
antigen 4 (CTLA-4) Ipilimumab Yervoy Ab Melanoma
Programmed cell death 1 
(PD-1)
Nivolumab Opdivo Ab Melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin’s lymphoma, head and neck cancer, urothelial cancer
Pembrolizumab Keytruda Ab
Melanoma, non-small cell lung cancer, head and neck cancer, classi-
cal Hodgkin’s lymphoma, microsatellite instability-high (MSI-H) /





Generic Name Trade Name
BRAF (V600E)
Vemurafenib Zelboraf KI Melanoma (BRAF/V600E)
Dabrafenib Tafinlar KI Melanoma (BRAF/V600E)
Bruton’s tyrosine kinase 
(BTK) Ibrutinib Imbruvica KI
Mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), 
Waldenstrom’s macroglobulinemia (WM)
CD20
Rituximab Rituxan Ab B cell non-Hodgkin’s lymphoma, MCL
Ibritumomab 
tiuxetan Zevalin Ab-RI B cell non-Hodgkin’s lymphoma, MCL
Ofatumumab Arzerra Ab CLL
CD30 Brentuximab vedotin Adcetris Ab-c
Relapsed or refractory Hodgkin’s lymphoma, anaplastic large cell 
lymphoma
CD33 Gemtuzumab ozogamicin Mylotarg Ab-c Relapsed or refractory acute myeloid leukemia (AML)
CD52 Alemtuzumab Campath Ab CLL
CCR4 MogamulizumabPoteligeo Ab Adult T-cell leukemia-lymphoma (ATL), peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL)
DNA methyltransferase 
(DNMT) Azacitidine Vidaza Myelodysplastic syndrome
Histone deacetylase (HDAC)
Vorinostat Zolinza CTCL
Romidepsin Istodax CTCL, PTCL
Panobinostat Farydak Multiple myeloma
Janus kinase (JAK) Ruxolitinib Jakafi KI Myelofibrosis
MAPK/ERK kinase (MEK) Trametinib Mekinist KI Melanoma (BRAF/V600E/K), non-small cell lung cancer
Proteasome
Bortezomib Velcade Multiple myeloma, MCL
Carfilzomib Kyprolis Multiple myeloma
Ixazomib Ninlaro Multiple myeloma
Receptor activator of 
nuclear factor kappa-B 
ligand (RANKL)
Denosumab Ranmark Ab Bone complications stemming from multiple myeloma and bone me-tastases from solid tumors, giant cell tumor of bone
SLAM Family Member 7 
(SLAMF7) Elotuzumab Empliciti Ab Multiple myeloma
Ab: antibody, Ab-c: antibody-drug conjugate, Ab-RI: radiotherapeutic antibody, Ab-Fc: VEGFR fused to the Fc portion of IgG, KI: 
kinase inhibitor. The table was created based on reference 2.
Table　1　Clinical applications of molecular targeted drugs (continued)
体薬には，①細胞膜上の受容体とリガンドの結合を
ブロックして受容体の活性化機構を遮断するもの

























Fig.　3　Mechanisms of cancer cell killing by antibody drugs. Antibody drugs can induce 
cancer cell killing in several ways including inhibition of the receptor-mediated signal 
transduction, delivery of payload (drug, radio-isotope), immune-mediated killing (antibody-
dependent cell cytotoxicity: ADCC, complement-dependent cytotoxicity: CDC), and inhi-
bition of immune checkpoint. TKI: tyrosine kinase inhibitor.
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Fig.　4　Tumor heterogeneity contributes to drug resistance. Kinase domain mutations, 
gene amplification, alternative signaling pathway, and stem cell properties result in drug 
resistance. TKI: tyrosine kinase inhibitor.
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Fig.　5　Basket and umbrella clinical trial designs. In a basket trial, a targeted therapy is 
evaluated on patients with a specific mutation in a variety of cancer types. Umbrella 
trial has various treatment arms in a single type of cancer.
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Table　2　Companion Diagnostics approved in Japan June 25, 2018
Companion Diagnostics (Trade Name) Corresponding Drug Biomarker
POTELIGEO TEST IHC/POTELIGEO TEST FCM mogamulizumab CCR4 protein
Cobas BRAF V600 mutation test vemurafenib BRAF mutation
Histofine ALK iAEP kit alectinib ALK protein
Vysis ALK Break Apart FISH probe kit crizotinib and alectinib ALK fusion
THxID BRAF kit dabrafenib/trametinib BRAF mutation
Cobas EGFR mutation test v2.0 osimertinib EGFR mutation
OncoGuide AmoyDx ROS1 Gene Fusions Detection Kit crizotinib ROS1 fusion (RNA)
PD-L1 IHC 22C3 pharmDx [Dako] pembrolizumab PD-L1 protein
Ventana OptiView ALK (D5F3) crizotinib and ceritinib ALK protein
MEBGEN RASKET-B kit cetuximab and panitumumab KRAS and NRAS mutation
BRACAnalyis CDx olaparib BRCA1 and BRCA2 mutation 
Oncomine Dx Target test dabrafenib/trametinib BRAF mutation
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